LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

1996: Introduction of law in Italy for early access to drugs (648/1996) to support rare disease patients

16/06/2021

Nominated by: Federchimica Assobiotec 

Organisation in nomination: Government of Italy

Early access programmes for novel medicines can benefit patients suffering from serious illnesses for which effective therapeutics are not yet available. For rare diseases, this is particularly important where no therapeutic alternatives are available, and the disease itself may be life-threatening or have a serious impact on the quality of life.  Access to such novel medicines outside clinical trials and prior to formal approval/reimbursement enables substantially greater benefits for citizens.

In 1996, Italy introduced in the national legislation Law 648/96, which allowed the reimbursement of certain medicinal products if no other therapeutic alternative was available, and provided that results phase II clinical trials, with favourable evaluation in terms of efficacy and safety, were available.  Eligible products were to be either:

  • Approved for commercialisation in other States, but not in Italy;
  • Not yet approved, but already subject to clinical trials;
  • To be used for a therapeutic indication different from that/those already authorized (off-label use).

Subsequently, Italy issued legislation regulating compassionate use and therapeutic use outside clinical trials (Ministerial Decree 8th May 2003, now replaced by Ministerial Decree 7th September 2017); and a Law (no. 326 of 24th November 2003) which established a fund covering named-patient reimbursement for not yet marketed “orphan medicinal products for rare diseases and medicinal products that represent a hope of cure for specific and serious diseases”.

These forms of early access to medicinal products can be considered one of the pillars on which the adaptive pathways approach is built. Adaptive pathways is a scientific concept for medicine development and data generation which allows for early and progressive patient access to a medicine. The approach makes use of the existing regulatory framework for medicines, and brings together different stakeholders such as regulators, Health Technology Assessment (HTA) bodies, medicine developers, health professionals and patients to agree on a prospective plan that allows the generation of data on a drug throughout its life cycle in areas of high unmet medical need, where it is difficult to collect data via traditional routes and where large clinical trials would unnecessarily expose patients who are unlikely to benefit from the medicine.

References:

  • Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer, Curr Pharm Des. 2012;18(25):3754-69. doi: 10.2174/138161212802002814

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.